RecruitingPhase 3NCT06456580
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis
Sponsor
Vor Biopharma
Enrollment
180 participants
Start Date
Jul 17, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Male or female patient aged ≥18 years at screening.
- Patients have prior confirmed diagnosis of gMG with generalized muscle weakness (typical pattern of weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) clinical classification II-IV.
- Patients have positive antibodies against AChR or MuSK at screening.
- MG-ADL score ≥6 points at screening and baseline with ocular-related score \<50% of the total score.
- QMG score ≥8 points, and ≥ 4 items score at least 2 points at screening and baseline.
Exclusion Criteria6
- Patients have been diagnosed with any other autoimmune disease which can potentially pose a safety or efficacy confounding risk.
- Patients having acute or chronic infection.
- Patients having thymoma within 5 years or received thymectomy ≤6 months prior to screening. Patients with thymoma diagnosed 3-5 years prior to screening may be eligible if thymoma was at a localized stage and definitively treated with complete surgical resection.
- Patients having current or history of primary immunodeficiency.
- Patients having history of malignancy within the last 5 years.
- Patient having prior or continuing diagnosis of serious cardiovascular, liver, kidney, respiratory system, endocrine or hematologic disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALTelitacicept
Subcutaneous injection
DRUGPlacebo
Subcutaneous injection
Locations(84)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06456580
Related Trials
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT0660762713 locations
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758110 locations
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT0674492093 locations
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
NCT0614955913 locations
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT060559599 locations